Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007612 | 1.00 | HPGD (0.41) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16994189 | 0.88 | HPGD (0.41) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2373406 | 0.79 | PTPN1 (0.35) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15007570 | 0.79 | PTPN1 (0.35) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2374014 | 0.74 | HPGD (0.42) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2941369 | 0.72 | HPGD (0.56) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31276129 | 0.72 | HPGD (0.49) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4941424 | 0.70 | HSP90AA1 (0.45) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16904122 | 0.69 | TSHR (0.51) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4484764 | 0.69 | CYP3A4 (0.44) | HPGDHSP90AA1HSP90AB1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550285-B1 | TRIOXACARCINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9611287-B2 | Trioxacarcins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160355537-A1 | TRIOXACARCINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-12-08 | — | — | US | disclosed |
| US-9102697-B2 | Trioxacarcins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130150314-A1 | TRIOXACARCINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2550285-A1 | TRIOXACARCINS AND USES THEREOF | President and Fellows of Harvard College (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119549-A1 | TRIOXACARCINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355537-A1 | TRIOXACARCINS AND USES THEREOF | PCSK9, PCSK7, PCSK6 | HPGD 2890/4885LMNA 685/4885MEN1 2208/4885 |
| US-20130150314-A1 | TRIOXACARCINS AND USES THEREOF | PCSK9, PCSK7, ABCC9 | HPGD 2873/4885LMNA 680/4885MEN1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.